Cangene in research pact for Alzheimer’s

Cangene (TSX:CNJ) has signed a collaborative research agreement with the University of British Columbia to develop the work of Dr. Neil Cashman, scientific director of PrioNet Canada and Canada Research Chair in Neurodegeneration and Protein Misfolding at UBC, aimed at developing immune-based therapies for Alzheimer’s disease. Cangene became interested in the program following a recent [...]

Cangene taps Sedor as CEO

Cangene (TSX:CNJ) has named John Sedor as president and CEO, effective Sept. 12, replacing Dr. John Langstaff, who stepped down last January to pursue personal interests. CFO Michael Graham, who has also been serving as interim president and CEO during the board’s search process, will continue in his role as CFO. Mr. Sedor most recently [...]

Cangene to leverage sales and marketing for acquisitions

Cangene (TSX:CNJ) hopes to parlay its new focus on sales and marketing as a stepping stone to acquire products from Big Pharma. “We’ve always been profitable, have money in the bank and have been looking for ways to spend our money to enhance our business,” CEO John Langstaff told biotuesdays.com in an exclusive interview.  “One [...]

Cangene to begin distributing WinRho in the U.S.

Cangene (TSX:CNJ) will assume the U.S. distribution of its WinRho SDF on June 1, 2010 from Baxter Healthcare, which had been selling the immune globulin IV product since March, 2005. “This move is in line with our increasing focus on our commercial products, particularly in the important U.S. market,” Cangene CEO Dr. John Langstaff said [...]

Analysts hike Cangene price targets

Versant Partners raised its 12-month price target on Cangene (TSX:CNJ) to $11 from $10 after the drug maker’s fiscal 2009 profit blew through analysts’ forecasts. On Thursday, Winnipeg-based Cangene reported a  profit gain of 102% on revenue 44% higher for the fiscal year ended July 31,  sending its stock price soaring $1.84 to $6.39. Versant [...]